Fortress Biotech (FBIO) investor relations material

Strategic highlights and business model

• Focuses on commercial dermatology and clinical-stage assets in rare diseases, oncology, and dermatology, leveraging a diversified portfolio and unique acquisition model targeting validated clinical candidates and ex-US approved drugs on favorable terms.

• Generates revenue through product sales, royalties, equity dividends, and strategic transactions, with a scalable model supported by multiple subsidiaries and partner companies.

• Employs partnerships with leading academic institutions and global pharmaceutical companies to enhance development and commercialization.

Recent milestones and financial achievements

• Achieved three FDA approvals since Q4 2024, including Emrosi for rosacea, Unloxcyt for cSCC, and Zycubo for Menkes Disease.

• Sold a Priority Review Voucher for Zycubo for $205M in March 2026 and received $28M upfront from the sale of Checkpoint Therapeutics, with additional milestone and royalty potential.

• Product revenue reached $61M in 2025 from eight marketed dermatology products.

• Portfolio companies are eligible for significant milestone payments and royalties, such as up to $128M for Zycubo and up to $125M for CAEL-101.

Pipeline and portfolio overview

• Pipeline includes 14 candidates (8 clinical, 6 preclinical) across oncology, rare diseases, and dermatology, with multiple late-stage and registration-phase assets.

• Notable assets: Emrosi (rosacea), Unloxcyt (cSCC), Zycubo (Menkes Disease), Anselamimab/CAEL-101 (AL amyloidosis), Dotinurad (gout), and Triplex (CMV, HIV, NHL).

• Ongoing clinical trials in high unmet need areas, including CAR-T and gene therapies for glioblastoma, Duchenne muscular dystrophy, and other rare conditions.